Related Experiment Video

Updated: Feb 12, 2026

Generation of Induced-pluripotent Stem Cells Using Fibroblast-like Synoviocytes Isolated from Joints of Rheumatoid Arthritis Patients
09:31

Generation of Induced-pluripotent Stem Cells Using Fibroblast-like Synoviocytes Isolated from Joints of Rheumatoid Arthritis Patients

Published on: October 16, 2016

9.9K

Methylglyoxal: A Relevant Marker of Disease Activity in Patients with Rheumatoid Arthritis

Ines Knani1, Hassan Bouzidi2, Saoussen Zrour3

  • 1Laboratory of Biochemistry, LR12ES05, Faculty of Medicine, University of Monastir, Monastir, Tunisia.

Disease Markers
|April 3, 2018
PubMed
Abstract

Insights

Methylglyoxal (MGO) and soluble receptor for advanced glycation end products (sRAGE) are linked to rheumatoid arthritis (RA) disease activity. Higher MGO levels correlate with increased RA activity, while sRAGE levels decrease with higher disease severity.

Area of Science:

  • Biochemistry
  • Immunology
  • Rheumatology

Background:

  • The role of methylglyoxal (MGO) and soluble receptor for advanced glycation end products (sRAGE) in rheumatoid arthritis (RA) pathogenesis remains unclear.
  • Investigating the association between MGO, sRAGE, and RA disease activity is crucial for understanding disease mechanisms.

Purpose of the Study:

  • To determine the relationship between serum MGO and sRAGE levels and disease activity in patients with rheumatoid arthritis.
  • To assess the independent association of MGO and sRAGE with the presence of active disease in RA.

Main Methods:

  • A cross-sectional study involving 80 RA patients and 30 healthy controls.
  • Disease activity in RA was quantified using the disease activity score for 28 joints (DAS28).
  • Serum MGO and sRAGE concentrations were measured using enzyme-linked immunosorbent assay (ELISA).

Main Results:

  • Serum MGO levels were significantly elevated in RA patients compared to controls (P < 0.001) and increased with higher disease activity (P = 0.019).
  • Serum sRAGE concentrations were significantly lower in RA patients with high disease activity compared to those with moderate activity and controls (P = 0.004; P = 0.002).
  • Multiple logistic regression revealed MGO as an independent predictor of active RA (OR = 1.17, 95% CI: 1.02-1.31, P = 0.01).

Conclusions:

  • Serum MGO and sRAGE levels exhibit an inverse correlation with rheumatoid arthritis activity.
  • Elevated serum MGO is independently associated with increased disease activity in rheumatoid arthritis.

More Related Videos

Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass07:44

Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass

Published on: July 14, 2023

1.7K
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.2K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
234
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
223
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.2K
Co-activators and Co-repressors02:04

Co-activators and Co-repressors

Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
8.7K
Patient-centered Care01:13

Patient-centered Care

Patient-centered care involves delivering care beyond inpatient hospitalization. Reflective practice can enhance a patient-centered approach. Reflective practice is a process of reasoning that considers all aspects of the present situation, including practicalities, learning from personal practice, and consideration of patient needs. Patients appreciate care decisions made while considering their input. Involving the patient in their care provides the patient with a sense of contribution rather...
3.1K
tRNA Activation02:26

tRNA Activation

Aminoacyl-tRNA synthetases are present in both eukaryotes and bacteria. Though eukaryotes have 20 different aminoacyl-tRNA synthetases to couple to 20 amino acids, many bacteria do not have genes for all of these aminoacyl-tRNA synthetases. Despite this, they still use all 20 amino acids to synthesize their proteins. For instance, some bacteria do not have the gene encoding the enzyme that couples glutamine with its partner tRNA. In these organisms, one enzyme adds glutamic acid to all of the...
23.1K